Development and Implementation of Venous Local Health District Thromboembolism Stewardship across a Hospital Network

Julianne Chong¹, Colin Curtain², Fady Gad³, Freda Passam⁴, Garry Soo¹, Russell Levy³, Scott Dunkley⁴, Nicole Wong Doo^{5,6}, Michelle Cunich^{7,8}, Rosemary Burke⁹, Vivien Chen^{5,10,11}

¹Concord Repatriation General Hospital, Pharmacy Department, ²University of Tasmania, School of Pharmacy and Pharmacology, ³Royal Prince Alfred Hospital, Pharmacy Department, ⁴Royal Prince Alfred Hospital, Department of Haematology, ⁵Concord Repatriation General Hospital, Department of Haematology, ⁶University of Sydney, Concord Clinical School, ⁷University of Sydney, Charles Perkins Centre, Faculty of Medicine and Health (Central Clinical School), ⁸Sydney Local Health District, Sydney Health Economics Collaborative, ⁹Executive Unit, Sydney Local Health District, ¹⁰Anzac Research Institute, Concord, ¹¹University of Sydney, Faculty of Medicine and Health

Background

- Venous thromboembolism (VTE) is a leading cause of preventable death Despite recommendations, many hospitalised patients do not receive VTE
- risk assessment and are not prescribed appropriate VTE prophylaxis¹ This is the first Australian study to explore the effectiveness of a VTE stewardship program to provide oversight of initiatives to prevent VTE

Aim

- ↑ Risk-appropriate VTE prophylaxis
- \uparrow VTE risk assessment using electronic clinical decision support (eCDS) tool, the VTE PowerPlan, Cerner®, Figure 1.
- 1 Any documented risk assessment
- ↓ Incidence of hospital acquired VTE (HA-VTE)

Methods




Figure 2. VTE stewardship design including Strategic Plan and Business Case

Results

Table 1. Results				
Appropriate VTE- Prophylaxis	• 78% → 88% • p =0.004			
eCDS Use	• 20% → 87% • p <0.001			
VTE Risk Assessment	• 71% → 93% • p <0.001			
HA-VTE	• 7.88 \rightarrow 6.99 events per 10,000 episodes of care, p=0.43			
Mean Cost	• \$0.82 per patient			
eCDS use associated with prescription of risk-appropriate VTE prophylaxis (p<0.001)				

Discussion

- Now a permanently funded program
- VTE stewardship provides for expansion of pharmacist role
- Electronic force function for risk assessment NOT implemented
- Prioritisation of positive engagement and culture change
- Future research: reasons for inappropriate prophylaxis

References

- Cohen AT et. al. Lancet. 2008;371:387-94.
- 2 Clinical Excellence Commission. VTE Prevention Audit: Auditor Reference Guide, 2020

	Suggested On: 4/01/2018 4:42 PM					
	Reason: All inpatients Require DVT Assessment					
			VTE Risk Assessment			
	12					
П		ň	*VTE Mechanical Prophylaxis contraindicated	1 CHECK, Other, Once		
		7	*VTE Chemoprophylaxis contraindicated	1 CHECK, Other, Once		
		নি	*VTE Prophylaxis not required (low risk)	1 CHECK, Other, Once		
		3	Mechanical Prophylaxis			
		Ø	graduated compression stockings (TEDs)	1 CHECK, Top, BD, VTE Prophylaxis, BOTH LEGS		
		0	intermittent pneumatic compression (calf compresso	1 CHECK, Top, BD, VTE Prophylaxis, BOTH LEGS		
			intermittent pneumatic compression (foot pumps)	1 CHECK, Top, BD, VTE Prophylaxis, BOTH LEGS		
		٢	Chemoprophylaxis			
		3	Unfractionated Heparin (UFH)			
		0	heparin	5,000 unit, Subcut, Soln, inj, BD, VTE Prophylaxis		
		0	heparin	5,000 unit, Subcut, Soln, inj, TDS, VTE Prophylaxis		
			Low Molecular Weight Heparin (LMWH)			
			If low/moderate risk surgery, use 20 mg daily. Dose reduction is required in renal impairment			
		7	enoxaparin (Clexane)	20 mg, Subcut, Inj, daily, VTE Prophylaxis		
		Ø.	enoxaparin (Clexane)	40 mq, Subcut, Inj. daily, VTE Prophylaxis		
			Used in Orthopaedics Only			
		Ø	dalteparin	2,500 unit, Subcut, Inj, daily, VTE Prophylaxis, Prophylaxis		
		0	dalteparin	5,000 unit, Subcut, Inj, daily, VTE Prophylaxis, Prophylaxis		
			Other Anticoagulants			
		۹	Doses should be adjusted in renal impairment. Contraindicated if:			
			Apixaban - CrCl < 25 mL/min Dabigatran - CrCl < 30 mL/min			
			Dabigatran - CrCl < 30 mL/min Fondaparinux - CrCl < 30 mL/min			
			Rivaroxban - CrCl < 15 mL/min			
П		17	apixaban	2.5 mg, Oral, Tablet, BD, VTE Prophylaxis, Anticoagulant		
		胬	dabigatran	220 mg, Oral, Capsule, daily, VTE Prophylaxis, Anticoagulant, Swallow whole.		
Ē		Ř	fondaparinux	2.5 mg, Subcut, Inj, daily, VTE Prophylaxis		
	-	岗	rivaroxaban	10 mg, Oral, Tablet, daily after food, VTE Prophylaxis, Anticoagulant		
•		ت		and the state of t		

Status

Detail:

Figure 1. VTE Risk Assessment eCDS tool: The VTE PowerPlan

Conclusion

This study demonstrates that investment in hospital VTE stewardship using eCDS is associated with significant improvements in clinical processes and outcomes at a relatively minor cost per patient

Acknowledgements

- Ben Maudlin, Hannah Turton, Brenda Shum
- This project has been supported by a Sydney Research Health Informatics Scholarship